{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:47:59Z","timestamp":1750308479855,"version":"3.41.0"},"publisher-location":"New York, NY, USA","reference-count":49,"publisher":"ACM","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,27]]},"DOI":"10.1145\/3543377.3543404","type":"proceedings-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T16:13:52Z","timestamp":1659975232000},"page":"175-183","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the Correlation between Immunogenomic Phenotype and Patient Outcomes in Prostate Cancer"],"prefix":"10.1145","author":[{"given":"HAOLIN","family":"LI","sequence":"first","affiliation":[{"name":"Crescent School,, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JASON","family":"TENG","sequence":"additional","affiliation":[{"name":"Crescent School,, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHUNBO","family":"HE","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"320","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"e_1_3_2_1_1_1","first-page":"394","volume":"2018","author":"Bray F","unstructured":"Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018 , 68(6): 394 - 424 . http:\/\/doi.org\/10.3322\/caac.21492 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, 68(6):394-424. http:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_2_1_2_1","volume-title":"Rim SH","author":"Li J","year":"2001","unstructured":"Li J , Djenaba JA , Soman A , Rim SH , Master VA : Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001 -2007. Prostate Cancer 2012, 2012:691380. http:\/\/doi.org\/10.1155\/2012\/691380 Li J, Djenaba JA, Soman A, Rim SH, Master VA: Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 2012, 2012:691380. http:\/\/doi.org\/10.1155\/2012\/691380"},{"key":"e_1_3_2_1_3_1","volume-title":"CMAJ 2020","author":"Brenner DR","year":"1912","unstructured":"Brenner DR , Weir HK , Demers AA , Ellison LF , Louzado C , Shaw A , Turner D , Woods RR , Smith LM , Canadian Cancer Statistics Advisory C : Projected estimates of cancer in Canada in 2020 . CMAJ 2020 , 192(9):E199-E205. http:\/\/doi.org\/10.1503\/cmaj. 1912 92 Brenner DR, Weir HK, Demers AA, Ellison LF, Louzado C, Shaw A, Turner D, Woods RR, Smith LM, Canadian Cancer Statistics Advisory C: Projected estimates of cancer in Canada in 2020. CMAJ 2020, 192(9):E199-E205. http:\/\/doi.org\/10.1503\/cmaj.191292"},{"key":"e_1_3_2_1_4_1","volume-title":"Milhem M: Cancer immunotherapy: recent advances and challenges. Ann Transl Med","author":"Swami U","year":"2021","unstructured":"Swami U , Milhem M: Cancer immunotherapy: recent advances and challenges. Ann Transl Med 2021 , 9(12):1032. http:\/\/doi.org\/10.4103\/jcrt.JCRT_1241_20 Swami U, Milhem M: Cancer immunotherapy: recent advances and challenges. Ann Transl Med 2021, 9(12):1032. http:\/\/doi.org\/10.4103\/jcrt.JCRT_1241_20"},{"key":"e_1_3_2_1_5_1","doi-asserted-by":"crossref","unstructured":"Steuer CE Ramalingam SS: Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer. JCO Oncol Pract 2021:OP2100305. http:\/\/doi.org\/10.1200\/OP.21.00305  Steuer CE Ramalingam SS: Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer. JCO Oncol Pract 2021:OP2100305. http:\/\/doi.org\/10.1200\/OP.21.00305","DOI":"10.1200\/OP.21.00305"},{"key":"e_1_3_2_1_6_1","volume-title":"Recent Advances in Cancer Immunotherapy. Biomolecules","author":"Suda K","year":"2021","unstructured":"Suda K : Recent Advances in Cancer Immunotherapy. Biomolecules 2021 , 11(2). http:\/\/doi.org\/10.3390\/biom11020335 Suda K: Recent Advances in Cancer Immunotherapy. Biomolecules 2021, 11(2). http:\/\/doi.org\/10.3390\/biom11020335"},{"key":"e_1_3_2_1_7_1","volume-title":"Dallos MC: Prostate Cancer Immunotherapy-Finally in From the Cold? Curr Oncol Rep","author":"Runcie KD","year":"2021","unstructured":"Runcie KD , Dallos MC: Prostate Cancer Immunotherapy-Finally in From the Cold? Curr Oncol Rep 2021 , 23(8):88. http:\/\/doi.org\/10.1007\/s11912-021-01084-0 Runcie KD, Dallos MC: Prostate Cancer Immunotherapy-Finally in From the Cold? Curr Oncol Rep 2021, 23(8):88. http:\/\/doi.org\/10.1007\/s11912-021-01084-0"},{"key":"e_1_3_2_1_8_1","first-page":"1387","volume":"2021","author":"Tsaur I","unstructured":"Tsaur I , Brandt MP , Juengel E , Manceau C , Ploussard G: Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World J Urol 2021 , 39(5): 1387 - 1403 . http:\/\/doi.org\/10.1007\/s00345-020-03497-1 Tsaur I, Brandt MP, Juengel E, Manceau C, Ploussard G: Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World J Urol 2021, 39(5):1387-1403. http:\/\/doi.org\/10.1007\/s00345-020-03497-1","journal-title":"World J Urol"},{"key":"e_1_3_2_1_9_1","first-page":"191","volume":"2021","author":"Rathi N","unstructured":"Rathi N , McFarland TR , Nussenzveig R , Agarwal N , Swami U: Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs 2021 , 81(2): 191 - 206 . http:\/\/doi.org\/10.1007\/s40265-020-01456-z Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U: Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs 2021, 81(2):191-206. http:\/\/doi.org\/10.1007\/s40265-020-01456-z","journal-title":"Metastatic Castration Refractory Prostate Cancer. Drugs"},{"key":"e_1_3_2_1_10_1","first-page":"1958","volume":"2021","author":"Xu Y","unstructured":"Xu Y , Song G , Xie S , Jiang W , Chen X , Chu M , Hu X , Wang ZW: The roles of PD-1\/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther 2021 , 29(6): 1958 - 1969 . https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.029 Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, Hu X, Wang ZW: The roles of PD-1\/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther 2021, 29(6):1958-1969. https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.029","journal-title":"Mol Ther"},{"key":"e_1_3_2_1_11_1","volume-title":"Wang J: Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis. Cancer Biomark","author":"Fan C","year":"2021","unstructured":"Fan C , Lu W , Li K , Zhao C , Wang F , Ding G , Wang J: Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis. Cancer Biomark 2021 . http:\/\/doi.org\/10.3233\/cbm-203222 Fan C, Lu W, Li K, Zhao C, Wang F, Ding G, Wang J: Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis. Cancer Biomark 2021. http:\/\/doi.org\/10.3233\/cbm-203222"},{"key":"e_1_3_2_1_12_1","volume-title":"Zhu B: Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. Front Immunol","author":"Zhang L","year":"2018","unstructured":"Zhang L , Zhao Y , Dai Y , Cheng JN , Gong Z , Feng Y , Sun C , Jia Q , Zhu B: Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. Front Immunol 2018 , 9:1578. http:\/\/doi.org\/10.3389\/fimmu.2018.01578 Zhang L, Zhao Y, Dai Y, Cheng JN, Gong Z, Feng Y, Sun C, Jia Q, Zhu B: Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. Front Immunol 2018, 9:1578. http:\/\/doi.org\/10.3389\/fimmu.2018.01578"},{"key":"e_1_3_2_1_13_1","first-page":"24","volume":"2018","author":"Beattie J","unstructured":"Beattie J , Yarmus L , Wahidi M , Rivera MP , Gilbert C , Maldonado F , Czarnecka K , Argento A , Chen A , Herth F : The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. Am J Respir Crit Care Med 2018 , 198(1): 24 - 38 . http:\/\/doi.org\/10.1164\/rccm.201712-2539PP Beattie J, Yarmus L, Wahidi M, Rivera MP, Gilbert C, Maldonado F, Czarnecka K, Argento A, Chen A, Herth F : The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. Am J Respir Crit Care Med 2018, 198(1):24-38. http:\/\/doi.org\/10.1164\/rccm.201712-2539PP","journal-title":"Minimally Invasive Pulmonary Procedures. Am J Respir Crit Care Med"},{"key":"e_1_3_2_1_14_1","first-page":"3717","volume":"2018","author":"Tamborero D","unstructured":"Tamborero D , Rubio-Perez C , Muinos F , Sabarinathan R , Piulats JM , Muntasell A , Dienstmann R , Lopez-Bigas N , Gonzalez-Perez A: A Pan -cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Clin Cancer Res 2018 , 24(15): 3717 - 3728 . http:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3509 Tamborero D, Rubio-Perez C, Muinos F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N, Gonzalez-Perez A: A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Clin Cancer Res 2018, 24(15):3717-3728. http:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3509","journal-title":"Infiltrating Immune Cell Populations. Clin Cancer Res"},{"key":"e_1_3_2_1_15_1","first-page":"812","volume":"2018","author":"Thorsson V","unstructured":"Thorsson V , Gibbs DL , Brown SD , Wolf D , Bortone DS , Ou Yang TH , Porta-Pardo E , Gao GF , Plaisier CL , Eddy JA : The Immune Landscape of Cancer. Immunity 2018 , 48(4): 812 - 830 e814. http:\/\/doi.org\/10.1016\/j.immuni.2018.03.023 Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA : The Immune Landscape of Cancer. Immunity 2018, 48(4):812-830 e814. http:\/\/doi.org\/10.1016\/j.immuni.2018.03.023","journal-title":"Cancer. Immunity"},{"key":"e_1_3_2_1_16_1","first-page":"399","volume":"2018","author":"Wellenstein MD","unstructured":"Wellenstein MD , de Visser KE: Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity 2018 , 48(3): 399 - 416 . http:\/\/doi.org\/10.1016\/j.immuni.2018.03.004 Wellenstein MD, de Visser KE: Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity 2018, 48(3):399-416. http:\/\/doi.org\/10.1016\/j.immuni.2018.03.004","journal-title":"Tumor Immune Landscape. Immunity"},{"key":"e_1_3_2_1_17_1","first-page":"1011","volume":"2018","author":"Anichini A","unstructured":"Anichini A , Tassi E , Grazia G , Mortarini R: The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. Cancer Immunol Immunother 2018 , 67(6): 1011 - 1022 . http:\/\/doi.org\/10.1007\/s00262-018-2147-7 Anichini A, Tassi E, Grazia G, Mortarini R: The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. Cancer Immunol Immunother 2018, 67(6):1011-1022. http:\/\/doi.org\/10.1007\/s00262-018-2147-7","journal-title":"Cancer Immunol Immunother"},{"key":"e_1_3_2_1_18_1","volume-title":"Dias S","author":"Gregorio AC","year":"2018","unstructured":"Gregorio AC , Lacerda M , Figueiredo P , Simoes S , Dias S , Moreira JN : Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathol Oncol Res 2018 , 24(4):701-716. http:\/\/doi.org\/10.1007\/s12253-017-0307-2 Gregorio AC, Lacerda M, Figueiredo P, Simoes S, Dias S, Moreira JN: Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathol Oncol Res 2018, 24(4):701-716. http:\/\/doi.org\/10.1007\/s12253-017-0307-2"},{"key":"e_1_3_2_1_19_1","volume-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal","author":"Gao J","year":"2013","unstructured":"Gao J , Aksoy BA , Dogrusoz U , Dresdner G , Gross B , Sumer SO , Sun Y , Jacobsen A , Sinha R , Larsson E : Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013 , 6(269):pl1. http:\/\/doi.org\/10.1126\/scisignal.2004088 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E : Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6(269):pl1. http:\/\/doi.org\/10.1126\/scisignal.2004088"},{"key":"e_1_3_2_1_20_1","first-page":"1011","volume":"2015","author":"Cancer Genome Atlas Research","unstructured":"Cancer Genome Atlas Research N: The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015 , 163(4): 1011 - 1025 . http:\/\/doi.org\/10.1016\/j.cell.2015.10.025 Cancer Genome Atlas Research N: The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015, 163(4):1011-1025. http:\/\/doi.org\/10.1016\/j.cell.2015.10.025","journal-title":"Primary Prostate Cancer. Cell"},{"key":"e_1_3_2_1_21_1","volume-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med","author":"Finotello F","year":"2019","unstructured":"Finotello F , Mayer C , Plattner C , Laschober G , Rieder D , Hackl H , Krogsdam A , Loncova Z , Posch W , Wilflingseder D : Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med 2019 , 11(1):34. http:\/\/doi.org\/10.1186\/s13073-019-0638-6 Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D : Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med 2019, 11(1):34. http:\/\/doi.org\/10.1186\/s13073-019-0638-6"},{"key":"e_1_3_2_1_22_1","volume-title":"Gfeller D: Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife","author":"Racle J","year":"2017","unstructured":"Racle J , de Jonge K , Baumgaertner P , Speiser DE , Gfeller D: Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife 2017 , 6. http:\/\/doi.org\/10.7554\/eLife.26476 Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D: Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife 2017, 6. http:\/\/doi.org\/10.7554\/eLife.26476"},{"key":"e_1_3_2_1_23_1","volume-title":"Wang J: Robust Principal Component Analysis based on Hypergraph Regularization for Sample Clustering and Co-characteristic Gene Selec-tion","author":"Gao Y","year":"2021","unstructured":"Gao Y , Wu M , Liu JX , Zheng CH , Wang J: Robust Principal Component Analysis based on Hypergraph Regularization for Sample Clustering and Co-characteristic Gene Selec-tion . IEEE\/ACM Trans Comput Biol Bioinform 2021 , PP. http:\/\/doi.org\/10.1109\/TCBB.2021.3065054 Gao Y, Wu M, Liu JX, Zheng CH, Wang J: Robust Principal Component Analysis based on Hypergraph Regularization for Sample Clustering and Co-characteristic Gene Selec-tion. IEEE\/ACM Trans Comput Biol Bioinform 2021, PP. http:\/\/doi.org\/10.1109\/TCBB.2021.3065054"},{"key":"e_1_3_2_1_24_1","first-page":"167","volume":"2021","author":"Margaritella N","unstructured":"Margaritella N , Inacio V , King R: Parameter clustering in Bayesian functional principal component analysis of neuroscientific data. Stat Med 2021 , 40(1): 167 - 184 . https:\/\/doi.org\/10.1002\/sim.8768 Margaritella N, Inacio V, King R: Parameter clustering in Bayesian functional principal component analysis of neuroscientific data. Stat Med 2021, 40(1):167-184. https:\/\/doi.org\/10.1002\/sim.8768","journal-title":"Stat Med"},{"key":"e_1_3_2_1_25_1","volume-title":"Pal D: Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression. Front Oncol","author":"Arora L","year":"2021","unstructured":"Arora L , Pal D: Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression. Front Oncol 2021 , 11:596798. http:\/\/doi.org\/10.3389\/fonc.2021.596798 Arora L, Pal D: Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression. Front Oncol 2021, 11:596798. http:\/\/doi.org\/10.3389\/fonc.2021.596798"},{"key":"e_1_3_2_1_26_1","volume-title":"Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers (Basel)","author":"Westergaard MCW","year":"2020","unstructured":"Westergaard MCW , Milne K , Pedersen M , Hasselager T , Olsen LR , Anglesio MS , Borch TH , Kennedy M , Briggs G , Ledoux S : Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers (Basel) 2020 , 12(12). https:\/\/doi.org\/10.3390\/cancers12123828 Westergaard MCW, Milne K, Pedersen M, Hasselager T, Olsen LR, Anglesio MS, Borch TH, Kennedy M, Briggs G, Ledoux S : Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers (Basel) 2020, 12(12). https:\/\/doi.org\/10.3390\/cancers12123828"},{"key":"e_1_3_2_1_27_1","first-page":"2015","volume":"2019","author":"Montes P","unstructured":"Montes P , Bernal M , Campo LN , Gonzalez-Ramirez AR , Jimenez P , Garrido P , Jurado M , Garrido F , Ruiz-Cabello F , Hernandez F: Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression. Cancer Immunol Immunother 2019 , 68(12): 2015 - 2027 . https:\/\/doi.org\/10.1007\/s00262-019-02420-x Montes P, Bernal M, Campo LN, Gonzalez-Ramirez AR, Jimenez P, Garrido P, Jurado M, Garrido F, Ruiz-Cabello F, Hernandez F: Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression. Cancer Immunol Immunother 2019, 68(12):2015-2027. https:\/\/doi.org\/10.1007\/s00262-019-02420-x","journal-title":"Cancer Immunol Immunother"},{"key":"e_1_3_2_1_28_1","first-page":"757","volume":"2019","author":"Georgouli M","unstructured":"Georgouli M , Herraiz C , Crosas-Molist E , Fanshawe B , Maiques O , Perdrix A , Pandya P , Rodriguez-Hernandez I , Ilieva KM , Cantelli G : Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. Cell 2019 , 176(4): 757 - 774 e723. https:\/\/doi.org\/10.1016\/j.cell.2018.12.038 Georgouli M, Herraiz C, Crosas-Molist E, Fanshawe B, Maiques O, Perdrix A, Pandya P, Rodriguez-Hernandez I, Ilieva KM, Cantelli G : Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. Cell 2019, 176(4):757-774 e723. https:\/\/doi.org\/10.1016\/j.cell.2018.12.038","journal-title":"Immune Microenvironment. Cell"},{"key":"e_1_3_2_1_29_1","volume":"2020","author":"Chen W","unstructured":"Chen W , Bi K , Zhang X , Jiang J , Diao H: In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. J Transl Autoimmun 2020 , 3:100067. https:\/\/doi.org\/10.1007\/s00262-020-02575-y Chen W, Bi K, Zhang X, Jiang J, Diao H: In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. J Transl Autoimmun 2020, 3:100067. https:\/\/doi.org\/10.1007\/s00262-020-02575-y","journal-title":"J Transl Autoimmun"},{"key":"e_1_3_2_1_30_1","first-page":"T51","volume":"2021","author":"Labrecque MP","unstructured":"Labrecque MP , Alumkal JJ , Coleman IM , Nelson PS , Morrissey C: The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. Endocr Relat Cancer 2021 , 28(8): T51 - T66 . https:\/\/doi.org\/10.1530\/ERC-21-0002 Labrecque MP, Alumkal JJ, Coleman IM, Nelson PS, Morrissey C: The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. Endocr Relat Cancer 2021, 28(8):T51-T66. https:\/\/doi.org\/10.1530\/ERC-21-0002","journal-title":"Endocr Relat Cancer"},{"key":"e_1_3_2_1_31_1","first-page":"2956","volume":"2020","author":"Harlemon M","unstructured":"Harlemon M , Ajayi O , Kachambwa P , Kim MS , Simonti CN , Quiver MH , Petersen DC , Mittal A , Fernandez PW , Hsing AW : A Custom Genotyping Array Reveals Population-Level Heterogeneity for the Genetic Risks of Prostate Cancer and Other Cancers in Africa. Cancer Res 2020 , 80(13): 2956 - 2966 . https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2165 Harlemon M, Ajayi O, Kachambwa P, Kim MS, Simonti CN, Quiver MH, Petersen DC, Mittal A, Fernandez PW, Hsing AW : A Custom Genotyping Array Reveals Population-Level Heterogeneity for the Genetic Risks of Prostate Cancer and Other Cancers in Africa. Cancer Res 2020, 80(13):2956-2966. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2165","journal-title":"Africa. Cancer Res"},{"key":"e_1_3_2_1_32_1","first-page":"207","volume":"2019","author":"Maitland NJ","unstructured":"Maitland NJ , Frame FM , Rane JK , Erb HH , Packer JR , Archer LK , Pellacani D: Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment. Adv Exp Med Biol 2019 , 1164: 207 - 224 . https:\/\/doi.org\/10.1007\/978-3-030-22254-3_16 Maitland NJ, Frame FM, Rane JK, Erb HH, Packer JR, Archer LK, Pellacani D: Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment. Adv Exp Med Biol 2019, 1164:207-224. https:\/\/doi.org\/10.1007\/978-3-030-22254-3_16","journal-title":"Treatment. Adv Exp Med Biol"},{"key":"e_1_3_2_1_33_1","first-page":"2020","volume":"2019","author":"Hellmann MD","unstructured":"Hellmann MD , Paz-Ares L , Bernabe Caro R , Zurawski B , Kim SW , Carcereny Costa E , Park K , Alexandru A , Lupinacci L , de la Mora Jimenez E : Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2019 , 381(21): 2020 - 2031 . https:\/\/doi.org\/10.1056\/NEJMoa1910231 Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E : Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2019, 381(21):2020-2031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"Advanced Non-Small-Cell Lung Cancer. N Engl J Med"},{"key":"e_1_3_2_1_34_1","volume-title":"Zhu HL","author":"Zhang WY","year":"2017","unstructured":"Zhang WY , Liu Y , Wang Y , Wang CM , Yang QM , Zhu HL , Han WD : Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduct Target Ther 2017 , 2:17054. https:\/\/doi.org\/10.1038\/sigtrans.2017.54 Zhang WY, Liu Y, Wang Y, Wang CM, Yang QM, Zhu HL, Han WD: Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduct Target Ther 2017, 2:17054. https:\/\/doi.org\/10.1038\/sigtrans.2017.54"},{"key":"e_1_3_2_1_35_1","volume-title":"Worel N: CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. Hemasphere","author":"Hopfinger G","year":"2019","unstructured":"Hopfinger G , Jager U , Worel N: CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. Hemasphere 2019 , 3(2):e185. https:\/\/doi.org\/10.1097\/HS9.0000000000000185 Hopfinger G, Jager U, Worel N: CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. Hemasphere 2019, 3(2):e185. https:\/\/doi.org\/10.1097\/HS9.0000000000000185"},{"key":"e_1_3_2_1_36_1","first-page":"29","volume":"2020","author":"Abramson","unstructured":"Abramson JS: Anti-CD19 CAR T-Cell Therapy for B- Cell Non-Hodgkin Lymphoma. Transfus Med Rev 2020 , 34(1): 29 - 33 . https:\/\/doi.org\/10.1016\/j.tmrv.2019.08.003 Abramson JS: Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. Transfus Med Rev 2020, 34(1):29-33. https:\/\/doi.org\/10.1016\/j.tmrv.2019.08.003","journal-title":"Cell Non-Hodgkin Lymphoma. Transfus Med Rev"},{"key":"e_1_3_2_1_37_1","volume":"2019","author":"Buchbinder EI","unstructured":"Buchbinder EI , Dutcher JP , Daniels GA , Curti BD , Patel SP , Holtan SG , Miletello GP , Fishman MN , Gonzalez R , Clark JI : Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer 2019 , 7(1):49. https:\/\/doi.org\/10.1186\/s40425-019-0522-3 Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI : Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer 2019, 7(1):49. https:\/\/doi.org\/10.1186\/s40425-019-0522-3","journal-title":"J Immunother Cancer"},{"key":"e_1_3_2_1_38_1","volume-title":"Bryant RJ","author":"Kwon JTW","year":"2021","unstructured":"Kwon JTW , Bryant RJ , Parkes EE : The tumor microenvironment and immune responses in prostate cancer patients. Endocr Relat Cancer 2021 , 28(8):T95-T107. https:\/\/doi.org\/10.1530\/ERC-21-0149 Kwon JTW, Bryant RJ, Parkes EE: The tumor microenvironment and immune responses in prostate cancer patients. Endocr Relat Cancer 2021, 28(8):T95-T107. https:\/\/doi.org\/10.1530\/ERC-21-0149"},{"key":"e_1_3_2_1_39_1","volume-title":"Swami U: Immune Checkpoint Inhibitors in Prostate Cancer. Cancers (Basel)","author":"Venkatachalam S","year":"2021","unstructured":"Venkatachalam S , McFarland TR , Agarwal N , Swami U: Immune Checkpoint Inhibitors in Prostate Cancer. Cancers (Basel) 2021 , 13(9). https:\/\/doi.org\/10.3390\/cancers13092187 Venkatachalam S, McFarland TR, Agarwal N, Swami U: Immune Checkpoint Inhibitors in Prostate Cancer. Cancers (Basel) 2021, 13(9). https:\/\/doi.org\/10.3390\/cancers13092187"},{"key":"e_1_3_2_1_40_1","first-page":"1","volume":"2021","author":"Sena LA","unstructured":"Sena LA , Denmeade SR , Antonarakis ES: Targeting the spectrum of immune checkpoints in prostate cancer. Expert Rev Clin Pharmacol 2021 : 1 - 14 . https:\/\/doi.org\/10.1080\/17512433.2021.1949287 Sena LA, Denmeade SR, Antonarakis ES: Targeting the spectrum of immune checkpoints in prostate cancer. Expert Rev Clin Pharmacol 2021:1-14. https:\/\/doi.org\/10.1080\/17512433.2021.1949287","journal-title":"Expert Rev Clin Pharmacol"},{"key":"e_1_3_2_1_41_1","volume":"2021","author":"Sinha M","unstructured":"Sinha M , Zhang L , Subudhi S , Chen B , Marquez J , Liu EV , Allaire K , Cheung A , Ng S , Nguyen C : Pre-existing immune status associated with response to combination of sipuleucel- T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer 2021 , 9(5). https:\/\/doi.org\/10.1136\/jitc-2020-002254 Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C : Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer 2021, 9(5). https:\/\/doi.org\/10.1136\/jitc-2020-002254","journal-title":"J Immunother Cancer"},{"key":"e_1_3_2_1_42_1","first-page":"e71","volume":"2021","author":"Williams KJ","unstructured":"Williams KJ , Allen RC: Immune Checkpoint Inhibitor-Induced Ptosis in a Patient With Prostate Cancer. J Neuroophthalmol 2021 , 41(1): e71 - e72 . https:\/\/doi.org\/10.1097\/WNO.0000000000000927 Williams KJ, Allen RC: Immune Checkpoint Inhibitor-Induced Ptosis in a Patient With Prostate Cancer. J Neuroophthalmol 2021, 41(1):e71-e72. https:\/\/doi.org\/10.1097\/WNO.0000000000000927","journal-title":"Patient With Prostate Cancer. J Neuroophthalmol"},{"key":"e_1_3_2_1_43_1","volume-title":"MSH2-deficient prostate tumors have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer Prostatic Dis","author":"McCoy P","year":"2021","unstructured":"McCoy P , Mangiola S , Macintyre G , Hutchinson R , Tran B , Pope B , Georgeson P , Hong MKH , Kurganovs N , Lunke S : MSH2-deficient prostate tumors have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer Prostatic Dis 2021 . https:\/\/doi.org\/10.1038\/s41391-021-00379-4 McCoy P, Mangiola S, Macintyre G, Hutchinson R, Tran B, Pope B, Georgeson P, Hong MKH, Kurganovs N, Lunke S : MSH2-deficient prostate tumors have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer Prostatic Dis 2021. https:\/\/doi.org\/10.1038\/s41391-021-00379-4"},{"key":"e_1_3_2_1_44_1","volume":"2021","author":"Ruiz de Porras V","unstructured":"Ruiz de Porras V , Pardo JC , Notario L , Etxaniz O , Font A: Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer? Int J Mol Sci 2021 , 22(9). https:\/\/doi.org\/10.3390\/ijms22094712 Ruiz de Porras V, Pardo JC, Notario L, Etxaniz O, Font A: Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer? Int J Mol Sci 2021, 22(9). https:\/\/doi.org\/10.3390\/ijms22094712","journal-title":"Int J Mol Sci"},{"key":"e_1_3_2_1_45_1","volume-title":"Fong L: How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis","author":"Stultz J","year":"2021","unstructured":"Stultz J , Fong L: How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 2021 . https:\/\/doi.org\/10.1038\/s41391-021-00340-5 Stultz J, Fong L: How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 2021. https:\/\/doi.org\/10.1038\/s41391-021-00340-5"},{"key":"e_1_3_2_1_46_1","volume-title":"Wu G: New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int","author":"Liu J","year":"2021","unstructured":"Liu J , Geng X , Hou J , Wu G: New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int 2021 , 21(1):389. https:\/\/doi.org\/10.1186\/s12935-021-02089-2 Liu J, Geng X, Hou J, Wu G: New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int 2021, 21(1):389. https:\/\/doi.org\/10.1186\/s12935-021-02089-2"},{"key":"e_1_3_2_1_47_1","volume-title":"Bremer E","author":"Cendrowicz E","year":"2021","unstructured":"Cendrowicz E , Sas Z , Bremer E , Rygiel TP : The Role of Macrophages in Cancer Development and Therapy. Cancers (Basel) 2021 , 13(8). https:\/\/doi.org\/10.3390\/cancers13081946 Cendrowicz E, Sas Z, Bremer E, Rygiel TP: The Role of Macrophages in Cancer Development and Therapy. Cancers (Basel) 2021, 13(8). https:\/\/doi.org\/10.3390\/cancers13081946"},{"key":"e_1_3_2_1_48_1","volume-title":"Luo Y: Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther","author":"Duan Z","year":"2021","unstructured":"Duan Z , Luo Y: Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther 2021 , 6(1):127. https:\/\/doi.org\/10.1038\/s41392-021-00506-6 Duan Z, Luo Y: Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther 2021, 6(1):127. https:\/\/doi.org\/10.1038\/s41392-021-00506-6"},{"key":"e_1_3_2_1_49_1","first-page":"231","volume":"2021","author":"Dong L","unstructured":"Dong L , Myers KV , Pienta KJ: Understanding the tumor-immune microenvironment in prostate cancer. Curr Opin Oncol 2021 , 33(3): 231 - 237 . https:\/\/doi.org\/10.1097\/CCO.0000000000000719 Dong L, Myers KV, Pienta KJ: Understanding the tumor-immune microenvironment in prostate cancer. Curr Opin Oncol 2021, 33(3):231-237. https:\/\/doi.org\/10.1097\/CCO.0000000000000719","journal-title":"Curr Opin Oncol"}],"event":{"name":"ICBBT 2022: 2022 14th International Conference on Bioinformatics and Biomedical Technology","acronym":"ICBBT 2022","location":"Xi'an China"},"container-title":["2022 14th International Conference on Bioinformatics and Biomedical Technology"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3543377.3543404","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3543377.3543404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:43:11Z","timestamp":1750272191000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3543377.3543404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":49,"alternative-id":["10.1145\/3543377.3543404","10.1145\/3543377"],"URL":"https:\/\/doi.org\/10.1145\/3543377.3543404","relation":{},"subject":[],"published":{"date-parts":[[2022,5,27]]}}}